Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations.
Background Effective risk stratification is essential for guiding treatment decisions in patients with metastatic renal cell carcinoma (mRCC). The Meet-URO score is a novel prognostic model that integrates the International Metastatic RCC Database Consortium (IMDC) criteria with neutrophil-to-lympho...
| Publicado en: | Oncologist Vol. 31; no. 7; pp. 1 - 12 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Oxford University Press / USA
Jul2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195281659&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 195281659 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10837159 IJ7 jtl: Oncologist issn: 10837159 maglogo: N pubinfo: dt: Jul2026 vid: 31 iid: 7 pid: 622 pub: Oxford University Press / USA artinfo: ui: 195281659 195281659 197171167 195281659 10.1093/oncolo/oyag203 195281659 ppf: 1 ppct: 11 formats: tig: atl: Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations. aug: au: Rebuzzi, Sara Elena Ghose, Aruni Rudman, Sarah Venugopal, Balaji Young, Kate Frazer, Ricky Dylan Ayodele, Olubukola Stares, Mark O'Carrigan, Brent Ali, Waqas affil: Medical Oncology Unit 2, Ospedale Molinette, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, 10126, Italy sug: subj: Carcinoma, Renal Cell Drug Therapy Carcinoma, Renal Cell Prognosis Neoplasm Metastasis Prognosis Immunotherapy Methods Antineoplastic Agents, Combined Therapeutic Use Human Male Female Middle Age Aged Multicenter Studies Retrospective Design Record Review Nonexperimental Studies Survival Analysis Overall Survival Progression-Free Survival Validation Studies Karnofsky Performance Status Hemoglobins Calcium Albumins Neutrophils Platelet Count Kaplan-Meier Estimator Log-Rank Test Confidence Intervals Odds Ratio Logistic Regression Multivariate Analysis Cox Proportional Hazards Model Data Analysis Software Descriptive Statistics Middle Aged: 45-64 years Aged: 65+ years Male Female ab: Background Effective risk stratification is essential for guiding treatment decisions in patients with metastatic renal cell carcinoma (mRCC). The Meet-URO score is a novel prognostic model that integrates the International Metastatic RCC Database Consortium (IMDC) criteria with neutrophil-to-lymphocyte ratio (NLR) and the presence of bone metastases. Developed in the immunotherapy era, it has demonstrated superior prognostic accuracy compared to the IMDC score across various clinical settings and treatment strategies. Its validation in the context of first-line immune-based combinations has been awaited. Methods External validation of Meet-URO was performed using a large retrospective real-world cohort of mRCC patients treated with first-line immune-based combinations. Secondary analyses included a comparison with the IMDC score for predicting overall survival (OS) and progression-free survival (PFS). Additionally, restricted mean survival time (RMST) was assessed. Results A total of 1,418 patients were included in the analysis: 54% received ICI–ICI regimen (nivolumab plus ipilimumab), while 46% received the ICI–TKI combination. At baseline, 52.5% of patients had an NLR ≥ 3.2, and 32% had bone metastases. After a median follow-up of 26.8 months, the median OS and median PFS were 34.7 and 11.3 months, respectively. Meet-URO demonstrated effective prognostic stratification, identifying patient groups with markedly different outcomes (median OS 11.5-51.4 months; 3-year OS 26-66%; RMST 20.0-42.8 months). Compared to IMDC, Meet-URO showed a significantly better OS (c-index 0.675 vs 0.643; Δc = 0.032, P < .001) and PFS (c-index 0.60 vs 0.58; P < .001) prediction performance. Conclusions Meet-URO demonstrated robust prognostic accuracy. Its integration into routine clinical practice and use as a stratification factor in clinical trials may support more personalized treatment strategies and enhance clinical trial design. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|